From the *Bascom Palmer Eye Institute, Miami, FL; †Retina and Vitreous of Louisiana, Baton Rouge, LA; ‡Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, SC; §School of Medicine, Medical College of Georgia, Augusta, GA; ¶Southeast Retina Center, Augusta, Georgia, GA; and ∥Departments of Epidemiology and Ophthalmology, Callahan Eye Foundation Hospital, University of Alabama at Birmingham, AL.
Disclosure: M. N. Lott, none; J. J. Fuller, none; H. A. Hancock, none; J. Singh, none; H. Singh, Schering-Plough sponsored this investigator-initiated study; G. McGwin, none; D. M. Marcus, Schering-Plough and Alcon sponsored this investigator-initiated study. Other support for research includes Eyetech OSI, Alimaera, Regeneron, Allergan. Consulting assignments with Eyetech OSI and Novartis.
Supported by Schering-Plough, Inc. (provision of moxifloxacin tablets) and Alcon Laboratories, Inc. (analysis of vitreous specimens).
Reprint requests: McGregor N. Lott, MD, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136; e-mail: [email protected].
